Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Key Inclusion Criteria:~* HCV treatment-naive adult participants (18-65 years of age) with chronic HCV infection and plasma HCV RNA ≥ 5 log10 IU/mL at screening~* Agree to use protocol defined precautions against pregnancy~Key Exclusion Criteria:~* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, α1 antitrypsin deficiency, cholangitis)~* Evidence of cirrhosis~* Evidence of current drug abuse~* Screening laboratory results outside the protocol specified requirements~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Velpatasvir 5 mg (GT 1a) (Type: EXPERIMENTAL): Participants with genotype (GT) 1a HCV infection will receive velpatasvir 5 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 25 mg (GT 1a) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 50 mg (GT 1a) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 100 mg (GT 1a) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive velpatasvir 100 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 150 mg (GT 1a) (Type: EXPERIMENTAL): Participants with GT 1a HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 150 mg (GT 1b) (Type: EXPERIMENTAL): Participants with GT 1b HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 150 mg (GT 2) (Type: EXPERIMENTAL): Participants with GT 2 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 25 mg (GT 3) (Type: EXPERIMENTAL): Participants with GT 3 HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 50 mg (GT 3) (Type: EXPERIMENTAL): Participants with GT 3 HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 150 mg (GT 3) (Type: EXPERIMENTAL): Participants with GT 3 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir 150 mg (GT 4) (Type: EXPERIMENTAL): Participants with GT 4 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
- Velpatasvir up to 400 mg (GT 2) (Type: EXPERIMENTAL): Participants with GT 2 HCV infection will receive velpatasvir up to 400 mg or placebo once daily for 3 days under fasted conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete